Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Be More Vigilant About Proposed Clinical Trial Exclusions

Executive Summary

FDA’s Bob Temple says “document” being drafted will instruct reviewers to pay more attention during sponsor meetings and eliminate unnecessary exclusions from protocols.

You may also be interested in...

Labeling Would Include More Subgroup Findings Under Revised Guidance

FDA’s updated draft on clinical pharmacology says some specific population data should be included in labeling, regardless of whether response differences were found.

Failed Pediatric Study Data To Get FDA Review At Patient Meeting

Agency officials plan discussion of how analysis of failed pediatric clinical trial data can improve future trials during annual patient network meeting.

The Sound Of Silence: FDA Ponders How To Label When No Subgroup Difference Found

Clinical trial diversity meeting may broach the subject of whether drug labels should indicate that subgroup differences were explored, but none found.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts